Browse Category

NASDAQ:OMER.O News 8 January 2026

Omeros stock rises in premarket after $36,000-a-vial Yartemlea price is set

Omeros stock rises in premarket after $36,000-a-vial Yartemlea price is set

Omeros Corp shares rose about 4% to $14.09 premarket after setting a $36,000 price for each vial of newly approved Yartemlea, used to treat TA-TMA in transplant patients. The company began its U.S. launch Jan. 2 and reported $171.5 million in cash at year-end. Shares jumped 6.6% in after-hours trading Wednesday. Analysts raised price targets following the announcement.

Stock Market Today

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

7 February 2026
Disney shares closed up 3.6% at $108.70 Friday, recovering from earlier losses as U.S. stocks rallied and the Dow topped 50,000. Investors are watching Super Bowl streaming economics and Disney’s CEO transition, with Josh D’Amaro set to take over at the March 18 meeting. Disney reported quarterly revenue of $25.98 billion and adjusted EPS of $1.63, while segment operating income fell 9% to $4.6 billion.
Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

7 February 2026
Novo Nordisk Class B shares closed up 5.3% at 295.50 Danish crowns in Copenhagen after Hims & Hers said it would stop offering a compounded pill version of Wegovy following U.S. regulatory warnings. The move came after Novo called the Hims product “illegal mass compounding” and threatened legal action. Shares had fallen nearly 8% Thursday after Hims launched the pill. Trading resumes Monday.
Go toTop